MX9504802A - Anticuerpos anti-egfr y fvs de cadena simple anti-egfr. - Google Patents

Anticuerpos anti-egfr y fvs de cadena simple anti-egfr.

Info

Publication number
MX9504802A
MX9504802A MX9504802A MX9504802A MX9504802A MX 9504802 A MX9504802 A MX 9504802A MX 9504802 A MX9504802 A MX 9504802A MX 9504802 A MX9504802 A MX 9504802A MX 9504802 A MX9504802 A MX 9504802A
Authority
MX
Mexico
Prior art keywords
chain fvs
egfr
egfr antibodies
phage
antibody libraries
Prior art date
Application number
MX9504802A
Other languages
English (en)
Inventor
A Cathrine Kettleborough
Mary M Bendig
Keith H Ansell
Detlef Gussow
Jaume Adan
Francesc Mitjans
Elisabeth Rosell
Francesc Blasco
Jaume Piulats
Original Assignee
Merck Patent Gmbh
Haftung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh, Haftung filed Critical Merck Patent Gmbh
Publication of MX9504802A publication Critical patent/MX9504802A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

Esta invencion se relaciona con anticuerpos anti-EGFR novedosos y Fvs de cadena simple (scFvs) de los mismos los cuales pueden obtenerse a partir de bibliotecas de anticuerpo de fago construidas a partir de células de un mamífero inmunizado, preferiblemente un raton. Dos de los Fvs de cadena simple aislados de las bibliotecas de anticuerpo de fago se diseñaron para crear moléculas de anticuerpo completo parcialmente humanizadas. Esos anticuerpos anti-EGFR quiméricos contienen regiones constantes de inmunoglobulinas humanas y pueden utilizarse también como el Fvs de cadena simple como agente para el diagnostico y terapia de tumores humanos.
MX9504802A 1994-03-17 1995-03-16 Anticuerpos anti-egfr y fvs de cadena simple anti-egfr. MX9504802A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP94104160 1994-03-17
EP94118970 1994-12-02
PCT/EP1995/000978 WO1995025167A1 (en) 1994-03-17 1995-03-16 Anti-egfr single-chain fvs and anti-egfr antibodies

Publications (1)

Publication Number Publication Date
MX9504802A true MX9504802A (es) 1997-05-31

Family

ID=26135522

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9504802A MX9504802A (es) 1994-03-17 1995-03-16 Anticuerpos anti-egfr y fvs de cadena simple anti-egfr.

Country Status (20)

Country Link
US (1) US5844093A (es)
EP (1) EP0699237B1 (es)
JP (2) JPH08510922A (es)
KR (1) KR100376038B1 (es)
AT (1) ATE232902T1 (es)
AU (1) AU2071695A (es)
CA (1) CA2163012C (es)
CZ (1) CZ292061B6 (es)
DE (1) DE69529649T2 (es)
DK (1) DK0699237T3 (es)
ES (1) ES2191702T3 (es)
HU (1) HU221001B1 (es)
MX (1) MX9504802A (es)
NO (1) NO322252B1 (es)
PL (1) PL181342B1 (es)
PT (1) PT699237E (es)
RU (1) RU2170257C2 (es)
SK (1) SK283889B6 (es)
UA (1) UA41929C2 (es)
WO (1) WO1995025167A1 (es)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2166368T3 (es) * 1993-12-24 2002-04-16 Merck Patent Gmbh Inmunoconjugados.
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
WO1998012227A1 (en) * 1996-09-19 1998-03-26 Diagnocure Inc. Recombinant single chain antibodies directed against the gp54 cancer marker, composition comprising same and use thereof
EP1500329B1 (en) * 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US6562599B1 (en) 1997-09-02 2003-05-13 Sumitomo Pharmaceuticals Company, Limited Single-stranded antibody against hepatitis B virus core protein, gene thereof, and therapeutic agent for hepatitis B containing these
DE19744531A1 (de) * 1997-10-09 1999-05-27 Klaus Dr Rer Nat Bosslet Bindemoleküle gegen Rezeptor-Ligand-Komplexe
ATE447613T1 (de) 1997-11-17 2009-11-15 Micromet Ag Verfahren zur identifikation von bindestellendomänen, die ihre epitopbindefähigkeit beibehalten
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
CN1183160C (zh) 1998-08-28 2005-01-05 基因技术股份有限公司 人抗因子IX/IXa抗体
IL146480A0 (en) * 1999-05-14 2002-07-25 Imclone Systems Inc Treatment of refractory human tumors with epidermal growth factor receptor antagonists
US7144991B2 (en) 1999-06-07 2006-12-05 Aletheon Pharmaceuticals, Inc. Streptavidin expressed gene fusions and methods of use thereof
US6790631B1 (en) * 1999-10-05 2004-09-14 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof
US7361338B2 (en) * 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
US20040091485A1 (en) * 2000-05-19 2004-05-13 Ellis John Robert Maxwell Humanised antibodies to the epidermal growth factor receptor
AU2001262750A1 (en) * 2000-06-14 2001-12-24 Medical And Biological Laboratories Co., Ltd. Method of constructing scfv antibody fused with fluorescent protein
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US7598055B2 (en) * 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
US8697394B2 (en) 2000-06-28 2014-04-15 Glycofi, Inc. Production of modified glycoproteins having multiple antennary structures
DE60139720D1 (de) * 2000-06-28 2009-10-08 Glycofi Inc Verfahren für die Herstellung modifizierter Glykoproteine
JP2004527456A (ja) * 2000-08-09 2004-09-09 イムクローン システムズ インコーポレイティド Ｅｇｆ受容体拮抗剤による過増殖性の疾患の治療
JP2004520011A (ja) * 2000-08-21 2004-07-08 スミスクライン・ビーチャム・コーポレイション Ｒａｎｋリガンド介在障害の治療において有用な抗−ｒａｎｋリガンドモノクローナル抗体
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
WO2002056910A1 (en) * 2001-01-17 2002-07-25 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
GB0103389D0 (en) * 2001-02-12 2001-03-28 Novartis Ag Organic compounds
ES2328796T3 (es) 2001-03-14 2009-11-18 Myriad Genetics, Inc. Interaccion tsg101-gag y uso de la misma.
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
WO2002092771A2 (en) 2001-05-11 2002-11-21 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
US20020193569A1 (en) * 2001-06-04 2002-12-19 Idec Pharmaceuticals Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
CN100497389C (zh) * 2001-06-13 2009-06-10 根马布股份公司 表皮生长因子受体(egfr)的人单克隆抗体
CA2472937C (en) 2002-01-11 2014-06-17 Biomarin Pharmaceutical, Inc. Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
US20050276812A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
US8034904B2 (en) * 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
MXPA05000403A (es) 2002-07-15 2005-07-22 Genentech Inc Metodos para identificar tumores que responden al tratamiento con anticuerpos contra erbb2.
US10919956B2 (en) 2002-11-12 2021-02-16 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
US20040147428A1 (en) * 2002-11-15 2004-07-29 Pluenneke John D. Methods of treatment using an inhibitor of epidermal growth factor receptor
US7332299B2 (en) 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
EP1622941A2 (en) * 2003-03-20 2006-02-08 ImClone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
DK1687338T3 (da) 2003-11-07 2011-02-07 Ablynx Nv Camelidae enkeltdomæne-antistoffer VHH, der er rettet mod epidermal vækstfaktor-receptor og anvendelser deraf
JP4734319B2 (ja) * 2004-03-19 2011-07-27 イムクローン・リミテッド・ライアビリティ・カンパニー ヒト抗上皮成長因子受容体抗体
PL1745075T3 (pl) 2004-04-21 2013-09-30 Brigham & Womens Hospital Inc Peptydy wiążące poli-N-acetyloglukozaminę (PNAG/DPNAG) i sposoby ich zastosowania
GB0410627D0 (en) * 2004-05-12 2004-06-16 Scancell Ltd Specific binding members
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
NZ580115A (en) 2004-09-23 2010-10-29 Genentech Inc Cysteine engineered antibody light chains and conjugates
SI1912675T1 (sl) 2005-07-25 2014-07-31 Emergent Product Development Seattle, Llc zmanjšanje števila celic B z uporabo molekul, ki se specifično vežejo na CD37 in CD20
US20100056439A1 (en) * 2005-12-06 2010-03-04 Domantis Limited Ligands that have binding specificity for egfr and/or vegf and methods of use therefor
US7503217B2 (en) * 2006-01-27 2009-03-17 Weatherford/Lamb, Inc. Sonar sand detection
WO2007102787A1 (en) 2006-03-06 2007-09-13 Agency For Science, Technology & Research Human embryonic stem cell methods and podxl expression
MX363905B (es) 2006-06-12 2019-04-08 Aptevo Res & Development Llc Proteinas de union multivalentes monocatenarias con funcion efectora.
EP2975057A1 (en) 2006-07-10 2016-01-20 Fujita Health University Novel anti-cd73 antibody
WO2008070780A1 (en) 2006-12-07 2008-06-12 Novartis Ag Antagonist antibodies against ephb3
WO2008077171A1 (en) * 2006-12-22 2008-07-03 Novelix Therapeutics Gmbh Treatment of diabetes by at least one epidermal growth factor receptor specific antibody or a derivative thereof
MX2009007987A (es) 2007-01-25 2010-03-01 Dana Farber Cancer Inst Inc Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante.
US9023356B2 (en) 2007-03-15 2015-05-05 Ludwig Institute For Cancer Research Ltd Treatment method using EGFR antibodies and SRC inhibitors and related formulations
WO2008154927A1 (en) * 2007-06-21 2008-12-24 Genmab A/S Novel methods for treating egfr-associated tumors
JP5532486B2 (ja) 2007-08-14 2014-06-25 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Ｅｇｆ受容体を標的とするモノクローナル抗体１７５ならびにその誘導体および用途
MX2010003099A (es) 2007-09-21 2010-05-17 Univ California Interferon de objetivo demuestra actividades potentes apoptoticas y antitumorales.
EP2132228B1 (en) 2008-04-11 2011-06-22 Emergent Product Development Seattle, LLC Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
CA2722466A1 (en) 2008-04-29 2009-11-05 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
CA2725666A1 (en) 2008-06-03 2009-12-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
AU2009256250B2 (en) 2008-06-03 2013-05-30 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
NZ590074A (en) 2008-07-08 2012-12-21 Abbott Lab Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
KR20110031393A (ko) 2008-07-21 2011-03-25 더 브리검 앤드 우먼즈 하스피털, 인크. 합성 베타-1,6 글루코사민 올리고당에 관한 방법 및 조성물
KR101108642B1 (ko) * 2009-09-29 2012-02-09 주식회사 녹십자 표피 성장 인자 수용체에 특이적으로 결합하는 항체
KR20140015139A (ko) 2009-10-15 2014-02-06 애브비 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US20120282274A1 (en) * 2009-11-20 2012-11-08 Northshore University Health System Research Institute Targeting of the c-terminal segment of c.difficile toxin b for improved clinical diagnosis, prevention, and treatment
CA2781682A1 (en) 2009-12-04 2011-06-09 Genentech, Inc. Multispecific antibodies, antibody analogs, compositions, and methods
CN102167743B (zh) * 2010-02-25 2014-05-14 上海百迈博制药有限公司 一种全人源抗egfr单克隆抗体、其制备方法及用途
RU2624027C2 (ru) 2010-04-23 2017-06-30 Дженентек, Инк. Получение гетеромультимерных белков
WO2011152525A1 (ja) * 2010-06-04 2011-12-08 東亞合成株式会社 抗体およびその利用
CA2807014A1 (en) 2010-08-03 2012-02-09 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
TW201211252A (en) 2010-08-26 2012-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
KR101273918B1 (ko) * 2010-09-17 2013-06-13 강원대학교산학협력단 인간 항-상피세포성 성장인자수용체 Ｆａｂ 항체 및 이를 포함하는 종양 치료용 약학 조성물
EA201390472A1 (ru) 2010-10-29 2014-02-28 Иммьюноджен, Инк. Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты
AU2011320318B9 (en) 2010-10-29 2015-11-19 Immunogen, Inc. Non-antagonistic EGFR-binding molecules and immunoconjugates thereof
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
CA2825064C (en) 2011-02-04 2022-08-30 Genentech, Inc. Fc variants and methods for their production
CN103561771B (zh) 2011-03-17 2019-01-04 伯明翰大学 重新定向的免疫治疗
JP6208658B2 (ja) 2011-07-05 2017-10-04 バイオアシス テクノロジーズ インコーポレイテッド ｐ９７−抗体結合体および使用方法
EP2739649B1 (en) 2011-08-05 2017-09-27 Bioasis Technologies Inc. P97 fragments with transfer activity
MX357391B (es) 2011-09-30 2018-07-06 Regeneron Pharma Anticuerpos anti-erbb3 y usos de los mismos.
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
KR102037541B1 (ko) 2011-10-28 2019-10-29 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 폴리펩티드 구축물 및 이의 용도
CA2856411A1 (en) 2011-11-21 2013-05-30 Immunogen, Inc. Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate
UY34558A (es) 2011-12-30 2013-07-31 Abbvie Inc Proteínas de unión específicas duales dirigidas contra il-13 y/o il-17
EP2827906A1 (en) * 2012-03-21 2015-01-28 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Novel photoimmunoconjugates for use in photodynamic therapy
CN104918956A (zh) * 2012-05-17 2015-09-16 索伦托治疗有限公司 与egfr结合的抗原结合蛋白
TWI641619B (zh) 2012-06-25 2018-11-21 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
EP2880156B1 (en) 2012-07-31 2017-08-23 biOasis Technologies Inc Dephosphorylated lysosomal storage disease proteins and methods of use thereof
AU2013337775B2 (en) 2012-11-01 2017-03-30 Abbvie Inc. Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof
CN105263958B (zh) 2013-03-13 2019-09-27 比奥阿赛斯技术有限公司 p97片段及其应用
CN105324396A (zh) 2013-03-15 2016-02-10 艾伯维公司 针对IL-1β和/或IL-17的双重特异性结合蛋白
EA033115B1 (ru) 2013-04-29 2019-08-30 Тева Фармасьютикалз Острэйлиа Пти Лтд. АНТИТЕЛА ПРОТИВ CD38 И СЛИТЫЕ БЕЛКИ С ОСЛАБЛЕННЫМ ИНТЕРФЕРОНОМ АЛЬФА-2b
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
EP3038657A2 (en) 2013-08-28 2016-07-06 Bioasis Technologies Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
JP6603227B2 (ja) 2014-02-03 2019-11-06 バイオアシス テクノロジーズ インコーポレイテッド Ｐ９７融合タンパク質
DK3107562T3 (da) 2014-02-19 2019-12-16 Bioasis Technologies Inc P97-ids-fusionsproteiner
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
US10058619B2 (en) 2014-05-01 2018-08-28 Bioasis Technologies, Inc. P97-polynucleotide conjugates
CN106456768B (zh) 2014-06-13 2019-12-03 腾博龙公司 含有抗egfr1抗体的缀合物
IL251822B2 (en) 2014-10-29 2023-03-01 Teva Pharmaceuticals Australia Pty Ltd Variants of interferon alpha-2-b
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
WO2017201488A1 (en) 2016-05-20 2017-11-23 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
US11618784B2 (en) 2016-07-19 2023-04-04 Teva Pharmaceuticals Australia Pty Ltd. Anti-CD47 combination therapy
WO2018152033A1 (en) * 2017-02-14 2018-08-23 Promab Biotechnologies, Inc. Cd47-car-t cells
EP3589662A4 (en) 2017-02-28 2020-12-30 Harpoon Therapeutics, Inc. INDUCTIBLE MONOVALENT ANTIGBINDING PROTEIN
JP7090347B2 (ja) 2017-05-12 2022-06-24 ハープーン セラピューティクス，インク． メソテリン結合タンパク質
CR20200195A (es) 2017-10-13 2020-08-14 Harpoon Therapeutics Inc Proteínas de unión a antigenos de maduraciòn de celulas b
CN109879964B (zh) * 2017-12-06 2022-08-05 北京科立思维生物科技有限公司 抗egfr单链抗体、抗pd1单链抗体及融合蛋白
WO2019195959A1 (en) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
JP2022514262A (ja) 2018-12-17 2022-02-10 レビトープ リミテッド 双子型免疫細胞エンゲージャー
EP4142778A1 (en) * 2020-04-30 2023-03-08 Board of Regents, The University of Texas System Anti-cd79b antibodies and chimeric antigen receptors and methods of use thereof
EP3954393A1 (en) 2020-08-13 2022-02-16 Bioasis Technologies Inc. Combination therapies for delivery across the blood brain barrier
CA3187272A1 (en) 2020-10-08 2022-04-14 Thorsten Ross Trispecific binders
CA3216098A1 (en) 2021-07-30 2023-02-02 Uwe Reusch Duplexbodies
AU2022382368A1 (en) 2021-11-03 2024-05-02 Affimed Gmbh Bispecific cd16a binders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2016842A1 (en) * 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
US5395750A (en) * 1992-02-28 1995-03-07 Hoffmann-La Roche Inc. Methods for producing proteins which bind to predetermined antigens
GB9401182D0 (en) * 1994-01-21 1994-03-16 Inst Of Cancer The Research Antibodies to EGF receptor and their antitumour effect

Also Published As

Publication number Publication date
EP0699237B1 (en) 2003-02-19
KR100376038B1 (ko) 2003-06-09
NO322252B1 (no) 2006-09-04
UA41929C2 (uk) 2001-10-15
NO954626D0 (no) 1995-11-16
NO954626L (no) 1995-11-16
US5844093A (en) 1998-12-01
AU2071695A (en) 1995-10-03
DE69529649D1 (de) 2003-03-27
PL181342B1 (pl) 2001-07-31
CZ301495A3 (en) 1996-02-14
SK283889B6 (sk) 2004-04-06
HUT73461A (en) 1996-08-28
EP0699237A1 (en) 1996-03-06
ATE232902T1 (de) 2003-03-15
DE69529649T2 (de) 2003-12-18
PT699237E (pt) 2003-07-31
WO1995025167A1 (en) 1995-09-21
PL311661A1 (en) 1996-03-04
JP2006025794A (ja) 2006-02-02
CZ292061B6 (cs) 2003-07-16
SK143095A3 (en) 1996-11-06
CA2163012A1 (en) 1995-09-21
CA2163012C (en) 2009-12-08
HU221001B1 (hu) 2002-07-29
HU9503285D0 (en) 1996-02-28
ES2191702T3 (es) 2003-09-16
JPH08510922A (ja) 1996-11-19
RU2170257C2 (ru) 2001-07-10
DK0699237T3 (da) 2003-05-26

Similar Documents

Publication Publication Date Title
MX9504802A (es) Anticuerpos anti-egfr y fvs de cadena simple anti-egfr.
US9409976B2 (en) CDIM binding proteins and uses thereof
HUP0101160A2 (hu) Humán szöveti faktor (TF) elleni humanizált antitest és eljárás előállítására
Maleki et al. Future prospects of monoclonal antibodies as magic bullets in immunotherapy
BRPI0316779B1 (pt) anticorpo humanizado que liga cd20 humano, composição, artigo manufaturado, método de indução da apoptose, método de tratamento de câncer cd20 positivo, métodos de tratamento de doenças autoimunes, ácidos nucléicos isolados, vetores de expressão, células hospedeiras, método para a produção de um anticorpo 2h7 humanizado, polipeptídeo isolado, formulação líquida, método de tratamento de artrite reumatóide (ra) e anticorpos de ligação de cd20 humanizados
GEP20074222B (en) Antibodies to cd40
WO1997002479A3 (en) Human monoclonal anti-tumor antibodies
ATE208820T1 (de) Humanisierte antikoerper
HUT65687A (en) Humanized and chimaeric monoclonal antibodies comprising of them pharmaceutical composition and the antibodies coding sequence containing of expression vectors, and process for the praparation of antibodies
NO942912L (no) Konstruksjon, kloning og ekspresjon av humaniserte, monoklonale antistoffer mot humant interleukin-5
DK0586002T3 (da) Monoklonale antistoffer, som genkender epidermisvækstfaktor-receptoren, celler og fremgangsmåder heraf og præparater indeho
Pereira et al. A model system for detection and isolation of a tumor cell surface antigen using antibody phage display
MD1374G2 (ro) Anticorpi monoclonali imunostimulatori, procedeu de obţinere a acestora, linii celulare, metodă de tratare a maladiilor şi compoziţie farmaceutică
MY145703A (en) Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumors
CA2012993A1 (en) Monoclonal antibodies (mabs) against tumor-associated antigens, the preparation and use thereof
SG146644A1 (en) Kid3 and kid3 antibodies that bind thereto
WO2002074251A3 (en) Monoclonal antibody therapy for pancreas cancer
WO2022034524A3 (en) Antibodies against ilt2 and use thereof
Asano et al. Application of the Fc fusion format to generate tag‐free bi‐specific diabodies
EP0155172A3 (en) Anti-human lung cancer monoclonal antibodies
WO2021254574A3 (en) Cd38 antibodies for the treatment of human diseases
WO2022015716A3 (en) Novel anti-pd1 antibodies for inhibiting t-cell activity
WO2023202672A9 (en) Antibodies targeting sirp-alpha and uses thereof
WO2023177974A3 (en) Anti-mesothelin antibodies and uses thereof
AU2022371521A1 (en) Antibodies binding cldn18.2 and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees